Press Release Distribution
Pricing
Customer Support
(800) 998-2927
Login
Log In
All Categories
Business
Entertainment
Health
Finance
Other
Tagged
p53-gene
Press Release
Sep 10, 2014
Critical Outcome Technologies Provides Updates Regarding its Lead Cancer Drug Candidate, COTI-2
COTI-2 demonstrates selective and potent anti-cancer p53-dependent activity in definitive experiments. Critical Outcome and MD Anderson Cancer Center sign letter of intent for phase 1 development of COTI-2.
Read More
First
Prev
1
Next
Last